Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scinai Immunotherapeutics Ltd.

2.81
+0.11614.31%
Post-market: 2.67-0.1400-4.98%16:38 EDT
Volume:3.70K
Turnover:10.21K
Market Cap:2.62M
PE:0.34
High:2.86
Open:2.70
Low:2.67
Close:2.69
Loading ...

Company Profile

Company Name:
Scinai Immunotherapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
31
Office Location:
Jerusalem BioPark,2nd floor,Hadassah Ein Kerem Campus,Jerusalem,Israel
Zip Code:
- -
Fax:
972 8 930 2531
Introduction:
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Directors

Name
Position
Mark Germain
Chairman of the Board
Ron Babecoff
Chief Executive Officer and Director
Adi Raviv
Director
Avner Rotman
Director
George H. Lowell
Director
Isaac Devash
Director
Morris Laster
Director
Ruth Ben Yakar
Director
Samuel Moed
Director
Yael Margolin
Director

Shareholders

Name
Position
Ron Babecoff
Chief Executive Officer and Director
Elad Mark
Chief Operating Officer
Uri Ben Or
Chief Financial Officer
Ester Abramov
QA Manager
Tamar Ben Yedidia
Chief Scientist